Results 41 to 50 of about 2,875 (114)

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Neurology and Therapy
Introduction The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer’s disease (AD) in the United States based on clinical data from the phase 3 ...
Malaz Boustani, Erin G. Doty, Louis P. Garrison Jr, Lee J. Smolen, Timothy M. Klein, Daniel R. Murphy, Andrew W. Spargo, Mark Belger, Joseph A. Johnston   +8 more
doaj   +1 more source

Reply to “CSF Amyloid‐β Risk Stratification in CAA: A Missing Link for Anti‐Amyloid Therapy Safety”

Annals of Neurology, Volume 100, Issue 5, Page 1118-1119, November 2026.
Philipp Arndt, Stefanie Schreiber
wiley   +1 more source

miR‐214‐3p and NCKAP1: A microglial functional dimension of Alzheimer's progression

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Biological Alzheimer's disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient‐derived induced microglia‐like cell (iMG) profiles capture a functional dimension of AD progression beyond conventional plasma biomarkers.
Min‐Young Noh, Yeonsil Moon, Sungwoo Kang, Won‐Jin Moon, Hee‐Jin Kim, Sang Won Seo, Sugyeong Ahn, Mi‐Hyeon Kang, Yong Sung Kim, Hyunkee Kim, Jae‐sung Bae, Hee Kyung Jin, Hojin Choi, Seong‐Ho Koh, Kee Hyung Park, Gregory S. Day, Guojun Bu, Seung Hyun Kim   +17 more
wiley   +1 more source

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Monoclonal antibodies (mAbs) for Alzheimer's disease (AD) represent major therapeutic advances, but their economic value is uncertain.
Tuyet Thao Nguyen, Bozhidar T. Chakalov, Megan Van Noord, Charles DeCarli, Jeffrey S. Hoch   +4 more
doaj   +1 more source

UK Dementia Trials Network: an expert‐informed framework for improving representation in dementia trials

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract Alzheimer's disease (AD) is the leading cause of dementia worldwide, yet clinical trials remain unrepresentative of those most affected. Ethnic minoritized groups, socioeconomically deprived communities, adults over 75, and populations in low‐ and middle‐income countries are consistently underrepresented, limiting generalizability and ...
Igor C. Fontana, Tara Comber, Sheena Aurora, Daniel J Blackburn, Rachel F. Buckley, Christine Chow, Tiffany W. Chow, Ruth Croney, Sebastian J. Crutch, Karen Chilcott Holdridge, Lynne Hughes, Christopher Kipps, Susan Kohlhaas, Jorge Llibre‐Guerra, Paresh Malhotra, Charles R. Marshall, Stella McCaughey, Richard James Oakley, Rema Raman, Daniel Ridley, Shardae Showell, Richard Tsai, Catherine J. Mummery   +22 more
wiley   +1 more source

Expert perspectives on the design and communication of endpoints in Alzheimer's disease clinical trials

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract Disease‐targeted therapies (DTTs) for Alzheimer's disease (AD) represent a major advance, yet challenges remain on how best to interpret and communicate their benefits. As clinical development increasingly targets the earliest stages of AD (before symptoms emerge and early symptomatic AD), there is a need for novel, complementary endpoints and
Pierre N. Tariot, Samuel P. Dickson, John Dwyer, Carlos Granda, Lynne Hughes, Jason Karlawish, Nicklas Linz, Kavita V. Nair, Russ Paulsen, Daniel Pawson, Robert Perneczky, Suzanne E. Schindler, Emily Scholler, James Taylor, Benjamin Tiede, George Vradenburg   +15 more
wiley   +1 more source

Preparedness and quality of dementia care in an Italian health authority when introducing anti‐Aβ therapies

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION We aimed to assess dementia care organizations within a southern Italian local health authority (Azienda Sanitaria Locale di Barletta Andria Trani) and to propose an equitable implementation framework for anti‐amyloid therapies.
Maurizio Giorelli, Claudia Ada Di Paola, Rosangela Vallarelli, Francesco Negri, Rosalba Morgese, Rosario Francesco Balzano, Pasquale Di Fazio, Daniela Tatò, Cataldo Procacci, Gianluca Masi, Federica Lucia Carpagnano, Tiziana Dimatteo   +11 more
doaj   +1 more source

Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis

Annals of Clinical and Translational Neurology, Volume 13, Issue 10, Page 2175-2183, October 2026.
Marcello Ciaccio, Luisa Agnello
wiley   +1 more source

Eligibility for anti‐amyloid treatment in a multiethnic community‐based study

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Introduction The approval of anti‐amyloid monoclonal antibodies (mAbs), including lecanemab and donanemab, represents a significant advance in disease‐modifying therapies (DMTs) for early Alzheimer's disease (AD).
Lydia Trudel, Joseph Therriault, Arthur C. Macedo, Karin L. Meeker, Meredith N. Braskie, Arthur W. Toga, Serge Gauthier, Paolo Vitali, Suzanne E. Schindler, Sid E. O'Bryant, Pedro Rosa‐Neto   +10 more
doaj   +1 more source

Advancements in Alzheimer's Disease Therapy: The Role of Anti-Amyloid Monoclonal Antibodies - A Literature Review

Journal of Education, Health and Sport
Alzheimer's disease is a neurodegenerative disorder characterized by progressive cognitive decline and neuronal damage. Anti-amyloid monoclonal antibodies such as aducanumab, lecanemab, and donanemab, represent the first disease-modifying therapies for ...
Agnieszka Skoczeń, Natalia Rutecka, Błażej Kaczmarek, Agata Kuśnierz-Gibała, Adrian Kruk, Michał Kulesza, Weronika Wawrzynów, Martyna Miłoś, Aleksandra Dorosz, Magdalena Maria Jakubowska   +9 more
doaj   +1 more source